Managing differential performance of polygenic risk scores across groups: Real-world experience of the eMERGE Network
- PMID: 38688278
- PMCID: PMC11179244
- DOI: 10.1016/j.ajhg.2024.04.005
Managing differential performance of polygenic risk scores across groups: Real-world experience of the eMERGE Network
Abstract
The differential performance of polygenic risk scores (PRSs) by group is one of the major ethical barriers to their clinical use. It is also one of the main practical challenges for any implementation effort. The social repercussions of how people are grouped in PRS research must be considered in communications with research participants, including return of results. Here, we outline the decisions faced and choices made by a large multi-site clinical implementation study returning PRSs to diverse participants in handling this issue of differential performance. Our approach to managing the complexities associated with the differential performance of PRSs serves as a case study that can help future implementers of PRSs to plot an anticipatory course in response to this issue.
Copyright © 2024 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.C.F.L. owns some stock in Fabric Genomics; E.D.E. is an employee and stockholder of Invitae, advisor and stockholder of Taproot Health, and advisor and stockholder of Exir; R.C.G. receives compensation for advising the following companies: Allelica, Atria, Fabric, Genomic Life, and Juniper Genomics; and is co-founder of Genome Medical and Nurture Genomics; E.E.K. has received personal fees from Regeneron Pharmaceuticals, 23&Me, Allelica, and Illumina; has received research funding from Allelica; and serves on the advisory boards for Encompass Biosciences, Overtone, and Galatea Bio; N.L. received personal fees from Illumina Inc; E.P. is a paid consultant for Allelica Inc.; M.S. is a member of the Institutional Review Board of the All of Us Research Program; J.W.S. is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity), has received grant support from Biogen, Inc., and is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments.
Figures


References
-
- Roberts D. The New Press; 2011. Fatal Invention: How Science, Politics, and Big Business Re-create Race in the Twenty-First Century.
Publication types
MeSH terms
Grants and funding
- U01 HG011167/HG/NHGRI NIH HHS/United States
- U01 HG011172/HG/NHGRI NIH HHS/United States
- U01 HG008657/HG/NHGRI NIH HHS/United States
- UL1 TR002541/TR/NCATS NIH HHS/United States
- U01 HG011169/HG/NHGRI NIH HHS/United States
- U01 HG008685/HG/NHGRI NIH HHS/United States
- U01 HG011181/HG/NHGRI NIH HHS/United States
- U01 HG011175/HG/NHGRI NIH HHS/United States
- K24 HL133373/HL/NHLBI NIH HHS/United States
- U01 HG008680/HG/NHGRI NIH HHS/United States
- U01 HG011176/HG/NHGRI NIH HHS/United States
- U01 HG006379/HG/NHGRI NIH HHS/United States
- U01 HG011166/HG/NHGRI NIH HHS/United States
LinkOut - more resources
Full Text Sources